Literature DB >> 10611616

On being the statistician on a Data and Safety Monitoring Board.

J Whitehead1.   

Abstract

Data and Safety Monitoring Boards (DSMBs) are commonly appointed to monitor emerging data from major clinical trials. This paper describes their organization and remit, and their relationship with other trial committees and structures. The operation of formal stopping rules for safety and efficacy by a DSMB is discussed. The duties of a DSMB, from pre-trial planning through to stopping a study are described in detail, with emphasis on the reporting of information to the DSMB and the reporting of conclusions by the DSMB. The issue of blindness is given prominence and the role of the statistician on the DSMB is explored in detail. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10611616     DOI: 10.1002/(sici)1097-0258(19991230)18:24<3425::aid-sim369>3.0.co;2-d

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Interim analyses and sequential designs in phase III studies.

Authors:  S Todd; A Whitehead; N Stallard; J Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

2.  Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.

Authors:  Yanqiu Weng; Yuko Y Palesch; Stacia M DeSantis; Wenle Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

3.  Maternal Perceptions of Safeguards for Research Involving Children.

Authors:  Maryam Rostami; Jane Paik Kim; Laura Turner-Essel; Laura Weiss Roberts
Journal:  J Child Fam Stud       Date:  2021-08-07

4.  Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials.

Authors:  Yanqiu Weng; Wenle Zhao; Yuko Palesch
Journal:  Pharm Stat       Date:  2012-05-16       Impact factor: 1.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.